Acute Kidney Injury in Hospitalized Patients Infected with COVID-19 from Wuhan, China: A Retrospective Study

Table 3

Treatment of patients infected with SARS-CoV-2 ().

Treatment	Patients with AKI	Patients without AKI	value
Diuretic	11 (30.56%)	18 (3.95%)	<0.001
Quinolone	34 (94.44%)	389 (85.31%)	0.13
First- or second-generation cephalosporins	0.00	22 (4.82%)	0.18
Penicillin	8 (22.22%)	88 (19.30%)	0.67
Antiviral	34 (94.44%)	393 (86.18%)	0.16
Glucocorticoid	23 (63.89%)	135 (29.61%)	<0.001
NSAID	8 (22.22%)	108 (23.68%)	0.84
PPI	23 (63.89%)	212 (46.49%)	0.04
Traditional Chinese medicine	2 (5.56%)	43 (9.43%)	0.44

Data are (%), where is the total number of patients with available data. values comparing patients with AKI and without AKI are from chi-square or Mann–Whitney test. SARS-CoV-2 = 2019 novel coronavirus; AKI = acute kidney injury; NSAID = nonsteroidal anti-inflammatory drugs; PPI = proton pump inhibitor.